samedan logo

 
 
spacer
home > pmps > autumn 2003 > complex pack assembly - clinical trials
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Complex Pack Assembly - Clinical Trials

The next 12 months are likely to see some fundamental development in the clinical trials process with the introduction of new EC legislation and a range of new pack innovations. But despite these changes, the fundamental key to success in any clinical trial will remain the strength of partnership between sponsor and packaging supplier.

In an ideal world, the date for a clinical trial would only be set when the schedule for pack production and distribution had been agreed between sponsor and packaging supplier. In reality however, the scope of a clinical trial can be vast, with some complex studies enrolling thousands of patients in several countries around the world. Therefore, it is understandable that in practice, patients are the priority for the sponsor and the packaging process has to fit in with pre-set targets and time scales. For this reason it is vital that the sponsor involves their packaging supplier as early as is possible within the trial process and that the two develop strong lines of communication and understanding. Clinical trials are by their nature unpredictable and having a reliable supplier on board early within the process will enable a flexible and effective solution to be found.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Pat Hobbs, Clinical Trials Technical Manager at Brecon Pharmaceuticals Ltd

Pat Hobbs is Clinical Trials Technical Manager at Brecon Pharmaceuticals Ltd. She has 26 years' experience in the pharmaceutical industry, and for the last 11 years has been involved in the quality assurance of investigational medicinal products.

spacer
Pat Hobbs
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency

How streamlining relations between central labs and mobile health providers can get the most from hybrid and decentralised clinical trials
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement